Alluvi: A Detailed Investigation into Retatrutide's Potential
Alluvi, known as BI 4744, presents a promising development in obesity care. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling effectiveness in research studies, possibly exceeding current GLP-1 target activa